USANA Health Sciences (USNA) Aktienübersicht
USANA Health Sciences, Inc. entwickelt, produziert und vertreibt wissenschaftlich fundierte Ernährungs-, Körperpflege- und Hautpflegeprodukte im asiatisch-pazifischen Raum, in Nord- und Südamerika sowie in Europa. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
USNA Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
USANA Health Sciences, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$13.76 |
| 52-Wochen-Hoch | US$32.32 |
| 52-Wochen-Tief | US$13.73 |
| Beta | 0.73 |
| 1 Monat Veränderung | -37.54% |
| 3 Monate Veränderung | -23.39% |
| 1 Jahr Veränderung | -56.02% |
| 3 Jahre Veränderung | -78.45% |
| 5 Jahre Veränderung | -85.43% |
| Veränderung seit IPO | 2,158.05% |
Aktuelle Nachrichten und Updates
Narrative-Update • Aug 05
USNA: Index Additions Will Support Future Stock Upside Despite Impairment
Analysts have revised their price target on USANA Health Sciences to $25.00 from $39.00, citing updated assumptions for revenue growth, profit margins, the discount rate, and future P/E expectations. What’s in the News for USANA Health Sciences USANA Health Sciences reported an estimated preliminary non cash goodwill impairment charge of US$29 million for the second quarter ended July 4, 2026, reflecting recent performance, changes in near term forecasts, and updated valuation assumptions under accounting standards.Seeking Alpha • Aug 05
USANA Health Sciences: No Clear Growth Engine Left (Rating Downgrade)
Summary USANA Health Sciences, Inc. stock fell sharply after Q2 earnings. The direct selling business has continued to shrink at quite a predictable pace. USNA's two growth brands, Hiya and Rise Wellness, showed a concerning performance. Revenues plummeted, and the brands' 2026 guidance was cut massively. After the report, I believe that USNA stock is cheap for good reason. I estimate a base scenario fair value of $18.1. Read the full article on Seeking AlphaRecent updates
Narrative-Update • Aug 05
USNA: Index Additions Will Support Future Stock Upside Despite Impairment
Analysts have revised their price target on USANA Health Sciences to $25.00 from $39.00, citing updated assumptions for revenue growth, profit margins, the discount rate, and future P/E expectations. What’s in the News for USANA Health Sciences USANA Health Sciences reported an estimated preliminary non cash goodwill impairment charge of US$29 million for the second quarter ended July 4, 2026, reflecting recent performance, changes in near term forecasts, and updated valuation assumptions under accounting standards.Seeking Alpha • Aug 05
USANA Health Sciences: No Clear Growth Engine Left (Rating Downgrade)
Summary USANA Health Sciences, Inc. stock fell sharply after Q2 earnings. The direct selling business has continued to shrink at quite a predictable pace. USNA's two growth brands, Hiya and Rise Wellness, showed a concerning performance. Revenues plummeted, and the brands' 2026 guidance was cut massively. After the report, I believe that USNA stock is cheap for good reason. I estimate a base scenario fair value of $18.1. Read the full article on Seeking AlphaNarrative-Update • Jun 17
USNA: Wellness Product Expansion And Buybacks Will Support Stock Upside
Analysts have maintained their $39.00 price target for USANA Health Sciences, citing largely unchanged assumptions for discount rate, revenue growth, profit margin, and future P/E in their updated models. What’s in the News for USANA Health Sciences USANA Health Sciences reiterated earnings guidance for fiscal 2026, with expected consolidated net sales of $925 million to $1.0b, net earnings of $20 million to $27 million, and diluted EPS of $1.11 to $1.45 per share.Narrative-Update • Jun 01
USNA: Skincare And Wellness Launches Will Support Future Upside Potential
Analysts have adjusted their price target for USANA Health Sciences to $39.00. Updated assumptions around discount rate, revenue growth, profit margin, and future P/E have shaped this new view on the stock.Analyseartikel • May 08
Results: USANA Health Sciences, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
As you might know, USANA Health Sciences, Inc. ( NYSE:USNA ) just kicked off its latest first-quarter results with some...Narrative-Update • Apr 26
USNA: Costco Expansion Of New Wellness Beverage Will Support Upside
Analysts have maintained their $39.0 price target for USANA Health Sciences, noting that small changes in the discount rate, revenue growth, profit margin, and future P/E assumptions in their updated models largely offset one another. What's in the News USANA Malaysia hosted a large slow jogging event on April 11, 2026, tied to the launch of its Vitamin D product, attracting over 1,000 onsite and online participants and earning a Malaysia Book of Records title for simultaneous acupressure slow jogging (Key Developments).Narrative-Update • Apr 08
USNA: Costco Beverage Rollout And CEO Return Will Support Upside
The updated analyst price target for USANA Health Sciences now aligns with a fair value estimate of $39.00, as analysts fine tune their assumptions for discount rate, revenue, profit margin and future P/E to reflect current conditions. What's in the News Subsidiary Rise Wellness launched Protein Pop Plus, a clear, carbonated ready to drink protein beverage with 30 grams of protein per 12 ounce can, now available at all 607 Costco locations across the United States, expanding on the original Protein Pop line sold at Target stores (Key Developments).Narrative-Update • Mar 25
USNA: CEO Return And Costco Distribution Expansion Will Support Future Upside
Analysts have made only a minimal adjustment to their fair value estimate for USANA Health Sciences, keeping it effectively unchanged at about $39.00. Small tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions offset each other.Narrative-Update • Mar 09
USNA: CEO Return And New Product Rollout Will Support Future Upside
Analysts have maintained their price target for USANA Health Sciences at about $39.00. This reflects only minor adjustments to assumptions about the discount rate, revenue growth, profit margin, and future P/E ratio, rather than a change in their overall view of the stock.Narrative-Update • Feb 22
USNA: CEO Return And Share Repurchases Will Support Future Upside
Analysts have nudged their price target for USANA Health Sciences slightly higher to $39, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E, which together point to a more refined view of the company’s valuation profile. What's in the News USANA Health Sciences plans to complete its long running share repurchase program announced in December 2015, having repurchased 8,544,925 shares, or 39.11%, for a total of $678.7 million.Narrative-Update • Feb 08
USNA: CEO Transition To Kevin Guest Will Support Future Upside
Analysts have held their price target for USANA Health Sciences at about $39.00. This reflects updated assumptions for a slightly lower discount rate, revenue growth, profit margin, and future P/E that together point to a broadly unchanged valuation view.Narrative-Update • Jan 24
USNA: Leadership Return And Index Removals Will Support Future Upside
Analysts have maintained their price target for USANA Health Sciences at US$39.00. This reflects a view that modestly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E still support the same fair value estimate.Narrative-Update • Jan 07
USNA: Index Removals And Steady Outlook Will Support Future Upside Potential
Analysts now hold their price target for USANA Health Sciences steady at about US$39, reflecting only minor tweaks to the discount rate, revenue growth, profit margin and forward P/E assumptions rather than a change in their overall view of the stock. What's in the News USANA Health Sciences, Inc.Narrative-Update • Dec 23
USNA: Index Removals Will Create Future Opportunity For Undervalued Upside Potential
Analysts have modestly raised their price target on USANA Health Sciences to 39.00 dollars from 39.00 dollars, reflecting slightly lower discount rate assumptions, materially higher projected revenue growth, a modestly lower profit margin outlook, and a marginally richer expected future price to earnings multiple. What's in the News Removed as a constituent from the S&P SmallCap 600 index, reducing passive index fund ownership and visibility among small cap investors (Index change notice).Narrative-Update • Dec 09
USNA: Active Acquisition Pursuits Will Drive Future Business Diversification Ahead
Analysts have modestly raised their price target on USANA Health Sciences to approximately $39.00, citing slightly higher long term growth assumptions and a marginal uptick in expected valuation multiples. What's in the News USANA Health Sciences was removed as a constituent from the S&P 600, S&P 1000, and S&P Composite 1500 indexes, as well as the S&P 600 Consumer Staples sector index, potentially reducing passive index fund ownership of the stock (Index Constituent Drops).Narrative-Update • Nov 25
USNA: Active M&A Efforts Will Drive Positive Business Diversification Ahead
Analysts have reiterated their price target for USANA Health Sciences at $39.00, citing consistent assumptions in revenue growth, profit margin, and valuation multiples. These factors support a stable outlook.Narrative-Update • Nov 08
USNA: Future Diversification Plans Will Drive Renewed Investor Optimism
Analysts have maintained their price target for USANA Health Sciences steady at $39.00. They cited consistent growth and profitability estimates as justification for holding the previous valuation.Narrative-Update • Oct 24
Share Repurchases And Product Expansion Will Drive Profitability And Brand Recognition
Analysts have revised their price target for USANA Health Sciences to $39.00. This reflects a recalibrated outlook based on modest revenue growth and improved profit margin expectations.Analyseartikel • Oct 16
USANA Health Sciences, Inc. (NYSE:USNA) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough
USANA Health Sciences, Inc. ( NYSE:USNA ) shareholders that were waiting for something to happen have been dealt a blow...Analyseartikel • Oct 11
Returns On Capital At USANA Health Sciences (NYSE:USNA) Paint A Concerning Picture
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...Narrative-Update • Oct 10
Modernized Sales Model And International Expansion Will Deliver Success
Analysts have significantly lowered their price target for USANA Health Sciences from $61 to $39. They cite reduced expectations for revenue growth and profit margins as key factors in the revised outlook.Analyseartikel • Jul 18
USANA Health Sciences, Inc. (NYSE:USNA) Looks Inexpensive But Perhaps Not Attractive Enough
USANA Health Sciences, Inc.'s ( NYSE:USNA ) price-to-earnings (or "P/E") ratio of 16.3x might make it look like a buy...Analyseartikel • May 12
Shareholders May Be Wary Of Increasing USANA Health Sciences, Inc.'s (NYSE:USNA) CEO Compensation Package
Key Insights USANA Health Sciences to hold its Annual General Meeting on 19th of May Total pay for CEO Jim Brown...Analyseartikel • Apr 08
The Market Doesn't Like What It Sees From USANA Health Sciences, Inc.'s (NYSE:USNA) Earnings Yet As Shares Tumble 25%
The USANA Health Sciences, Inc. ( NYSE:USNA ) share price has fared very poorly over the last month, falling by a...Analyseartikel • Apr 04
There Are Reasons To Feel Uneasy About USANA Health Sciences' (NYSE:USNA) Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...Analyseartikel • Dec 09
Should You Think About Buying USANA Health Sciences, Inc. (NYSE:USNA) Now?
USANA Health Sciences, Inc. ( NYSE:USNA ), might not be a large cap stock, but it received a lot of attention from a...Analyseartikel • Sep 26
USANA Health Sciences (NYSE:USNA) Could Be Struggling To Allocate Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Neues Narrative • Sep 24
India Expansion And Decisive Acquisitions Promise Growth Amid Analyst Concerns Over Shrinking Margins
Expansion into India and strategic acquisitions offer significant growth opportunities for USANA, potentially boosting revenue and diversifying its market presence.Analyseartikel • Sep 08
Is There Now An Opportunity In USANA Health Sciences, Inc. (NYSE:USNA)?
While USANA Health Sciences, Inc. ( NYSE:USNA ) might not have the largest market cap around , it saw significant share...Aktionärsrenditen
| USNA | US Personal Products | US Markt | |
|---|---|---|---|
| 7D | -8.2% | -1.0% | 0.09% |
| 1Y | -56.0% | -14.5% | 19.0% |
Rendite im Vergleich zur Industrie: USNA unter dem Niveau der Branche US Personal Products , die im vergangenen Jahr eine Rendite von -14.5% erzielte.
Rendite vs. Markt: USNA hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 19 erzielte.
Preisvolatilität
| USNA volatility | |
|---|---|
| USNA Average Weekly Movement | 11.6% |
| Personal Products Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: Der Aktienkurs von USNA war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: USNADie wöchentliche Volatilität (12%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1992 | 1,570 | Kevin Guest | www.usana.com |
USANA Health Sciences, Inc. entwickelt, produziert und vertreibt wissenschaftlich fundierte Ernährungs-, Körperpflege- und Hautpflegeprodukte im asiatisch-pazifischen Raum, in Nord- und Südamerika sowie in Europa. Das Unternehmen ist in zwei Segmenten tätig: Kernnahrungsmittel und Hiya Direct-To-Consumer. Das Unternehmen bietet USANA-Ernährungsoptimierer, einschließlich Nahrungsergänzungsmittel für die kardiovaskuläre Gesundheit, die Gesundheit des Skeletts und des Verdauungssystems; Essentials/CellSentials, wie Vitamin- und Mineralstoffpräparate für Kinder ab 13 Monaten; und Lebensmittelprodukte, die Mahlzeitenersatz-Shakes, Snack-Riegel und andere verwandte Produkte für ein gesundes Gewichtsmanagement, die Gesundheit des Verdauungssystems, Energie und Flüssigkeitszufuhr umfassen.
USANA Health Sciences, Inc.'s Grundlagenzusammenfassung
| USNA grundlegende Statistiken | |
|---|---|
| Marktanteil | US$254.05m |
| Gewinn(TTM) | -US$22.16m |
| Umsatz(TTM) | US$913.36m |
0.3x
Kurs-Umsatz-Verhältnis-11.5x
Kurs-Gewinn-Verhältnis Ist USNA zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| USNA Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$913.36m |
| Kosten der Einnahmen | US$206.00m |
| Bruttogewinn | US$707.36m |
| Sonstige Ausgaben | US$729.53m |
| Gewinn | -US$22.16m |
Zuletzt gemeldete Gewinne
Jul 04, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -1.20 |
| Bruttomarge | 77.45% |
| Nettogewinnspanne | -2.43% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich USNA auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/12 08:02 |
| Aktienkurs zum Tagesende | 2026/08/11 00:00 |
| Gewinne | 2026/07/04 |
| Jährliche Einnahmen | 2026/01/03 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
USANA Health Sciences, Inc. wird von 7 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| John San Marco | Brean Capital Historical (Janney Montgomery) |
| Scott Van Winkle | Canaccord Genuity |
| Stephanie Schiller Wissink | Jefferies LLC |